Both of our pre-clinical studies with adenine-induced CKD demonstrated positive changes in bone due to alterations in RANKL without changing PTH levels, indicating RANKL as an attractive potential therapy for mitigating bone changes in CKD. The gene discussed is TNFSF11; the disease is chronic kidney disease.